[go: up one dir, main page]

IT1269185B - Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2 - Google Patents

Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2

Info

Publication number
IT1269185B
IT1269185B ITMI940039A ITMI940039A IT1269185B IT 1269185 B IT1269185 B IT 1269185B IT MI940039 A ITMI940039 A IT MI940039A IT MI940039 A ITMI940039 A IT MI940039A IT 1269185 B IT1269185 B IT 1269185B
Authority
IT
Italy
Prior art keywords
effect
receptors
association
antagonist
synergic
Prior art date
Application number
ITMI940039A
Other languages
English (en)
Inventor
Claude Garret
Francois Montier
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ITMI940039A0 publication Critical patent/ITMI940039A0/it
Publication of ITMI940039A1 publication Critical patent/ITMI940039A1/it
Application granted granted Critical
Publication of IT1269185B publication Critical patent/IT1269185B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Soil Working Implements (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Associazioni dotate di effetto sinergico caratterizzato dal fatto di essere costituite da almeno un prodotto dotato di un'attività antagonista per i recettori NK1 e da almeno un prodotto dotato di una attività antagonista per i recettori NK2. Queste associazioni sono interessanti nel trattamento di affezioni in cui intervengono la sostanza P e/a la neurochinina A.
ITMI940039A 1993-01-19 1994-01-14 Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2 IT1269185B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300451A FR2700472B1 (fr) 1993-01-19 1993-01-19 Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.

Publications (3)

Publication Number Publication Date
ITMI940039A0 ITMI940039A0 (it) 1994-01-14
ITMI940039A1 ITMI940039A1 (it) 1995-07-14
IT1269185B true IT1269185B (it) 1997-03-21

Family

ID=9443143

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI940039A IT1269185B (it) 1993-01-19 1994-01-14 Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2

Country Status (25)

Country Link
US (1) US6177450B1 (it)
EP (1) EP0680323B1 (it)
JP (1) JP4341783B2 (it)
KR (1) KR100342152B1 (it)
AT (1) ATE150972T1 (it)
AU (1) AU682166B2 (it)
BE (1) BE1006705A3 (it)
CA (1) CA2152401C (it)
CH (1) CH687503A5 (it)
DE (1) DE69402411T2 (it)
DK (1) DK0680323T3 (it)
ES (2) ES2091712B1 (it)
FR (1) FR2700472B1 (it)
GB (1) GB2274777B (it)
GR (1) GR3023021T3 (it)
IE (1) IE940035A1 (it)
IL (1) IL108356A (it)
IT (1) IT1269185B (it)
LU (1) LU88442A1 (it)
NO (1) NO315077B1 (it)
NZ (1) NZ259728A (it)
PT (1) PT101444A (it)
TW (1) TW381021B (it)
WO (1) WO1994016697A1 (it)
ZA (1) ZA94333B (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
JPH10508837A (ja) * 1994-11-10 1998-09-02 ファイザー・インコーポレーテッド 眼の疾患を治療するためのnk−1レセプターアンタゴニスト
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
WO1998024446A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
FR2792835B3 (fr) 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
JP2007509184A (ja) * 2003-10-27 2007-04-12 ノバルティス アクチエンゲゼルシャフト 尿失禁の処置におけるニューロキニンアンタゴニストの使用
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
FR2678267B1 (fr) 1991-06-25 1994-02-04 Elf Sanofi Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant.
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5242930A (en) 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06507402A (ja) 1991-03-20 1994-08-25 ワーナー−ランバート・コンパニー 治療活性を有するα−置換ポリペプチド
FR2677361A1 (fr) * 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676054B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5773450A (en) 1991-06-20 1998-06-30 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (it) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509332A (ja) 1991-07-05 1994-10-20 メルク シヤープ エンド ドーム リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0536817A1 (en) 1991-07-05 1993-04-14 MERCK SHARP & DOHME LTD. Azabicyclic compounds as tachykinin antagonists
JPH06509090A (ja) 1991-07-10 1994-10-13 メルク シヤープ エンド ドーム リミテツド 芳香族化合物、それらを含む組成物、及び治療におけるそれらの使用
WO1993001159A1 (en) 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ATE136885T1 (de) 1991-08-20 1996-05-15 Merck Sharp & Dohme Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
JP2535134B2 (ja) 1991-09-16 1996-09-18 ファイザー・インコーポレーテッド 縮合三環式窒素含有複素環
EP0919245A3 (en) 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
JP2553020B2 (ja) 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
CA2324959C (en) 1991-11-12 2002-11-12 Pfizer Limited Phthalimido compounds as intermediates for producing substance p receptor antagonists
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
GB9201179D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
JP2656702B2 (ja) 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
FR2689888B1 (fr) 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0636130A1 (en) 1992-04-15 1995-02-01 Merck Sharp & Dohme Ltd. Azacyclic compounds
ES2164657T3 (es) 1992-05-18 2002-03-01 Pfizer Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.

Also Published As

Publication number Publication date
CA2152401C (fr) 2008-08-26
AU5862794A (en) 1994-08-15
US6177450B1 (en) 2001-01-23
JPH08505637A (ja) 1996-06-18
FR2700472B1 (fr) 1995-02-17
ITMI940039A1 (it) 1995-07-14
DE69402411D1 (de) 1997-05-07
GB9400691D0 (en) 1994-03-09
NO952828D0 (no) 1995-07-17
BE1006705A3 (fr) 1994-11-22
IL108356A (en) 1998-09-24
WO1994016697A1 (fr) 1994-08-04
CH687503A5 (fr) 1996-12-31
LU88442A1 (fr) 1994-10-03
PT101444A (pt) 1994-10-31
EP0680323A1 (fr) 1995-11-08
JP4341783B2 (ja) 2009-10-07
ES2091712A1 (es) 1996-11-01
IL108356A0 (en) 1994-04-12
NO952828L (no) 1995-07-17
ZA94333B (en) 1994-09-02
AU682166B2 (en) 1997-09-25
IE940035A1 (en) 1994-07-27
ITMI940039A0 (it) 1994-01-14
GB2274777A (en) 1994-08-10
KR100342152B1 (ko) 2003-02-26
GR3023021T3 (en) 1997-07-30
TW381021B (en) 2000-02-01
CA2152401A1 (fr) 1994-08-04
ES2100689T3 (es) 1997-06-16
NO315077B1 (no) 2003-07-07
GB2274777B (en) 1996-10-02
ATE150972T1 (de) 1997-04-15
FR2700472A1 (fr) 1994-07-22
ES2091712B1 (es) 1997-08-01
EP0680323B1 (fr) 1997-04-02
KR960700056A (ko) 1996-01-19
DK0680323T3 (da) 1997-10-20
DE69402411T2 (de) 1997-10-30
NZ259728A (en) 1996-05-28

Similar Documents

Publication Publication Date Title
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
NO2005015I2 (no) Terapeutisk aktiv forbindelse preparat inneholdende forbindelsen samt den anvendelse
NO924619L (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69814394D1 (de) Verwendung von levobupivacain
NO20005668D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
BR0012696A (pt) Composição oftálmica
CA2176298A1 (en) A single high dose fluoroquinolone treatment
SE9401540L (sv) Munhygienkomposition
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
ES2171665T3 (es) Derivados y conjugados de mdp que tienen una actividad que estimula la funcion hematopoyetica y las composiciones que contienen los mismos.
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971205